These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27043328)

  • 1. Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis.
    Wu Q; Gilbody S; Peckham E; Brabyn S; Parrott S
    Addiction; 2016 Sep; 111(9):1554-67. PubMed ID: 27043328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis.
    Peckham E; Brabyn S; Cook L; Tew G; Gilbody S
    BMC Psychiatry; 2017 Jul; 17(1):252. PubMed ID: 28705244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for smoking cessation and reduction in individuals with schizophrenia.
    Tsoi DT; Porwal M; Webster AC
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD007253. PubMed ID: 23450574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo.
    Littlewood RA; Claus ED; Wilcox CE; Mickey J; Arenella PB; Bryan AD; Hutchison KE
    Psychopharmacology (Berl); 2017 Dec; 234(23-24):3417-3429. PubMed ID: 28889258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
    Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
    Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch.
    Cunningham FE; Hur K; Dong D; Miller DR; Zhang R; Wei X; McCarren M; Mosholder AD; Graham DJ; Aspinall SL; Good CB
    Addiction; 2016 Jul; 111(7):1283-92. PubMed ID: 26826702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of varenicline adherence among smokers with HIV and its association with smoking cessation.
    Quinn MH; Bauer AM; Flitter A; Lubitz SF; Ashare RL; Thompson M; Leone F; Gross R; Schnoll R
    Addict Behav; 2020 Mar; 102():106151. PubMed ID: 31783245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.
    Anthenelli RM; Benowitz NL; West R; St Aubin L; McRae T; Lawrence D; Ascher J; Russ C; Krishen A; Evins AE
    Lancet; 2016 Jun; 387(10037):2507-20. PubMed ID: 27116918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.
    Tonstad S; Davies S; Flammer M; Russ C; Hughes J
    Drug Saf; 2010 Apr; 33(4):289-301. PubMed ID: 20297861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abstinence and relapse among smokers who use varenicline in a quit attempt-a pooled analysis of randomized controlled trials.
    Agboola SA; Coleman T; McNeill A; Leonardi-Bee J
    Addiction; 2015 Jul; 110(7):1182-93. PubMed ID: 25846123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis.
    Kishi T; Iwata N
    Eur Arch Psychiatry Clin Neurosci; 2015 Apr; 265(3):259-68. PubMed ID: 25283510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis.
    Siskind DJ; Wu BT; Wong TT; Firth J; Kisely S
    Lancet Psychiatry; 2020 Sep; 7(9):762-774. PubMed ID: 32828166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial.
    Tulloch HE; Pipe AL; Els C; Clyde MJ; Reid RD
    BMC Med; 2016 Jun; 14():80. PubMed ID: 27233840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological interventions for promoting smoking cessation during pregnancy.
    Coleman T; Chamberlain C; Davey MA; Cooper SE; Leonardi-Bee J
    Cochrane Database Syst Rev; 2015 Dec; (12):CD010078. PubMed ID: 26690977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study.
    Chengappa KN; Perkins KA; Brar JS; Schlicht PJ; Turkin SR; Hetrick ML; Levine MD; George TP
    J Clin Psychiatry; 2014 Jul; 75(7):765-72. PubMed ID: 25006684
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.